Swiss Re Tackles Longevity Drug Impact With Life Policy Advice

Swiss Re AG has issued new guidance for life insurance underwriters to assess applicants using medications, such as Metformin and Rapamycin, for longevity purposes. This move by a major reinsurer underscores the growing challenge and complexity these off-label or self-prescribed anti-aging drugs present for risk evaluation and underwriting practices within the life insurance industry.

Analysis

Swiss Re AG has issued new underwriting guidance to address the growing trend of individuals using medications for unapproved anti-aging or longevity purposes. The reinsurer specifically identified Metformin and rapamycin as substances being self-prescribed or used off-label, creating a new layer of complexity for risk assessment in the life insurance sector. This move by a major industry player signifies a formal acknowledgment of an emerging risk that challenges traditional underwriting models based on approved medical treatments and established mortality data. It highlights the industry's need to adapt to advancements in biotechnology and consumer health practices that fall outside conventional medical oversight, which introduces uncertainty into long-term liability calculations.

Key Decisions for Investors

• Investors in Swiss Re should view this as a sign of proactive risk management, positioning the company to better price complex longevity risks compared to competitors who may be slower to adapt.
• This development serves as a key indicator for the broader life insurance industry; investors should monitor how other insurers and reinsurers update their underwriting policies to avoid potential adverse selection from this emerging trend.
• The guidance underscores a long-term thematic shift, and investors in the healthcare and insurance sectors should consider the financial implications of off-label drug use for longevity on mortality and morbidity assumptions.